Bone Health and Osteoporosis
Shandong Boan Biotechnology Co. Ltd. is involved in clinical research centered on postmenopausal osteoporosis, with attention to maintaining bone mineral density and addressing bone loss in women after menopause.
- Postmenopausal osteoporosis
- Bone mineral density
- Bone resorption
The sponsor’s research focus includes comparative evaluation of therapies used in osteoporosis care, with interest in clinically relevant outcomes tied to skeletal strength and bone turnover.
Endocrine and Metabolic Disorders
The sponsor’s trial activity also reflects engagement in metabolic bone disease linked to hormonal changes after menopause, a domain where estrogen deficiency contributes to reduced bone integrity.
- Menopausal bone loss
- Bone metabolism
- Hormone-related skeletal decline
Its clinical interests extend to therapies that target the biological processes underlying bone remodeling and skeletal fragility.
Biologic Therapy and Comparative Clinical Evaluation
Research funded by the sponsor includes comparison of a biologic treatment with an established osteoporosis therapy, with emphasis on efficacy, safety, pharmacokinetics, and immunogenicity.
- Biologic medicines
- Comparative efficacy
- Immunogenicity
This area highlights therapeutic interest in agents designed for long-term management of bone fragility and related clinical outcomes.
Bone Turnover Biomarkers
The sponsor’s research landscape includes monitoring of bone resorption markers, particularly sCTX, to assess biological effects relevant to osteoporosis treatment.
- sCTX
- Bone turnover markers
- Pharmacodynamic response
These interests support clinical evaluation of therapies that influence osteoclast-mediated bone resorption and overall skeletal metabolism.
